Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial

Nov 5, 2024 · Third Quarter 2024 Financial Results: Cash Position: As of September 30, 2024, cash, cash equivalents and short-term investments were approximately $298.4 million, as …

CouponFollow Extension

$298
OFF

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial

1 week from now

Nov 5, 2024 · Third Quarter 2024 Financial Results: Cash Position: As of September 30, 2024, cash, cash equivalents and short-term investments were approximately $298.4 million, as …

globenewswire.com

14%
OFF

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial …

1 week from now

Nov 5, 2024 · Third Quarter and Recent Business Highlights. Revenue from global sales of IMCIVREE was $33.3 million for the third quarter of 2024, an increase of 14% percent on a …

yahoo.com

$33
OFF

RYTM - Rhythm Pharmaceuticals Reports Third Quarter 2024...

1 week from now

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) reported its third-quarter 2024 financial results, highlighting net revenue of $33.3 million from global sales of its obesity treatment, …

marketwirenews.com

48%
OFF

Rhythm Pharmaceuticals Third Quarter 2024 Earnings: Beats …

1 week from now

Nov 7, 2024 · Rhythm Pharmaceuticals (NASDAQ:RYTM) Third Quarter 2024 ResultsKey Financial Results. Revenue: US$33.3m (up 48% from 3Q 2023). Net loss: US$45.0m (loss …

yahoo.com

14%
OFF

Rhythm Pharmaceuticals Reports Strong Q3 Revenue Growth

1 week from now

Nov 6, 2024 · In the third quarter of 2024, Rhythm Pharmaceuticals reported net revenue of $33.3 million from global sales of its flagship product, IMCIVREE, marking a 14% increase from the …

businessinsider.com

$76
OFF

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial …

1 week from now

6 days ago · Third Quarter 2024 Financial Results. As of September 30, 2024, Milestone had cash, cash equivalents, and short-term investments of $76.4 million, compared to $66.0 million …

milestonepharma.com

$5
OFF

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

1 week from now

2 days ago · Summary of Financial Results for the Third Quarter 2024. The net loss for the three months ended September 30, 2024 was approximately $5.6 million compared to …

biospace.com

14%
OFF

Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call …

1 week from now

Nov 7, 2024 · Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) reported strong revenue growth with third-quarter revenues reaching $33.3 million, a 14% increase from the previous quarter. …

yahoo.com

$3
OFF

Cyclacel Pharmaceuticals Reports Third Quarter Financial ... - Nasdaq

1 week from now

5 days ago · As of September 30, 2024, cash equivalents totaled $3.0 million, compared to $3.4 million as of December 31, 2023. Net cash used in operating activities was $6.6 million for the …

nasdaq.com

$13
OFF

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

1 week from now

2 days ago · Net Loss: BioXcel Therapeutics had a net loss of $13.7 million for the third quarter of 2024, compared to a net loss of $50.5 million for the same period in 2023. The Company used …

biospace.com

$33
OFF

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial …

1 week from now

November 05, 2024 at 16:01 PM EST -- Third quarter 2024 net revenue from global sales of IMCIVREE ® (setmelanotide) of $33.3 million -- -- Adult patients with acquired hypothalamic …

financialcontent.com

$76
OFF

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial …

1 week from now

5 days ago · Third Quarter 2024 Financial Results As of September 30, 2024, Milestone had cash, cash equivalents, and short-term investments of $76.4 million, compared to $66.0 million …

businessinsider.com

$64
OFF

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial …

1 week from now

6 days ago · Net Loss: Net loss for the third quarter of 2024 was $64.8 million, or $0.18 per share, as compared to a net loss of $50.5 million, or $0.21 per share, in the corresponding period in …

morningstar.com

FAQs about Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Coupon?

What did Rhythm Pharmaceuticals do in Q3 2024?

ET -- BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the third quarter ended September 30, 2024. ...

What time will Rhythm Pharmaceuticals hold a conference call?

Rhythm Pharmaceuticals will host a live conference call and webcast at 5:00 p.m. ET today to review its third quarter 2024 financial results and recent business activities. Participants may register for the conference call here. It is recommended that participants join the call ten minutes prior to the scheduled start. ...

Why did Rhythm Pharmaceuticals reduce its 2024 operating expense guidance?

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) has reduced its 2024 operating expense guidance, indicating improved operating leverage and financial management. The company experienced a slight increase in cost of sales, primarily due to higher labor and overhead costs. ...

Why did Rhythm Pharmaceuticals lose $45 million?

Financially, Rhythm recorded a net loss of $45 million for the quarter, attributed to increased R&D and SG&A expenses. Looking forward, Rhythm Pharmaceuticals aims to complete various clinical trial enrollments by the end of 2024 and anticipates announcing top-line data from its Phase 3 trial for setmelanotide in the first half of 2025. ...

How did Rhythm Pharmaceuticals (Rytm) perform in Q3?

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) reported strong revenue growth with third-quarter revenues reaching $33.3 million, a 14% increase from the previous quarter. The company is making significant progress in its clinical programs, with the phase three trial for hypothalamic obesity on track for a data readout in the first half of 2025. ...

What did Marinus Pharmaceuticals do in the third quarter 2024?

RADNOR, Pa., November 12, 2024 -- (BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024. ...